Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dynavax (NASDAQ:DVAX), Adaptimmune Therapeutics (NASDAQ:ADAP) and ImmunoGen (NASDAQ:IMGN).
Dynavax (DVAX)
In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax, with a price target of $30. The company’s shares opened today at $12.09, close to its 52-week low of $10.35.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 9.2% and a 50.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Dynavax is a Moderate Buy with an average price target of $29.50, representing a 144.0% upside. In a report issued on October 8, J.P. Morgan also reiterated a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Adaptimmune Therapeutics (ADAP)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Adaptimmune Therapeutics yesterday. The company’s shares opened today at $7.55, close to its 52-week low of $6.60.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -7.0% and a 33.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Blueprint Medicines, and Loxo Oncology.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Strong Buy with an average price target of $17, implying a 125.2% upside from current levels. In a report released today, Raymond James also maintained a Buy rating on the stock with a $16 price target.
.
ImmunoGen (IMGN)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on ImmunoGen yesterday. The company’s shares opened today at $6.24.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 8.6% and a 41.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
ImmunoGen has an analyst consensus of Strong Buy, with a price target consensus of $19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
